Alto Neuroscience completes enrollment in Phase 2 trial for first-of-its-kind schizophrenia cognitive treatment
Alto met its enrollment goal with 83 patients across 13 US clinical sites
Alto met its enrollment goal with 83 patients across 13 US clinical sites
The NIRSE-GAL study, conducted in Galicia, Spain, is the first real-world, population-based investigation of a universal RSV immunization program spanning two consecutive seasons
Bocunebart works by blocking pituitary adenylate cyclase-activating polypeptide
This approval represents the seventh FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx with KEYTRUDA
Operational leverage kicked in during the quarter, with adjusted EBITDA rising 21% year-on-year to Rs 147 crore
Chemicals delivered improved efficiency and optimal capacity utilization, with EBIT rising 37% YoY
The surge has been driven largely by COCO stores, with 755 COCO and 165 FOFO outlets added this fiscal year
Subscribe To Our Newsletter & Stay Updated